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Abstract 
Treatment in medical oncology is gradually shifting from the use of non-specific chemotherapeutic 
agents towards an era of novel targeted therapy in which drugs and their combinations target 
specific aspects of the biology of tumor cells. Multiple myeloma (MM) has become one of the best 
examples in this regard, reflected in the identification of new pathogenic mechanisms, together with 
the development of novel drugs that are being explored from the preclinical setting to the early 
phases of clinical development. We review the biological rationale for the use of the most important 
new agents for treating MM and summarize their clinical activity in an increasingly busy field. 
First, we discuss data from already approved and active agents (including second- and third-
generation- proteasome inhibitors, immunomodulatory agents (IMIDs) and alkylators). Then we 
focus on agents with novel mechanisms of action, such as monoclonal antibodies (MoAb), cell 
cycle specific drugs, deacetylase inhibitors, agents acting on the unfolded protein response, 
signaling transduction pathway inhibitors, and kinase inhibitors. 
Among this plethora of new agents or mechanisms some are specially promising: Anti-CD38 
MoAb, such as daratumumab, are the first antibodies with clinical activity as single agents in MM. 
Also the kinesin spindle protein inhibitor Arry-520 is effective in monotherapy as well as in 
combination with dexamethasone in heavily pretreated patients. Immunotherapy against MM is also 
being explored, and probably the most attractive example of this approach is the combination of the 
anti-CS1 MoAb elotuzumab with lenalidomide and dexamethasone, that has produced exciting 
results in the relapsed/refractory setting. 
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Introduction 
Therapeutics in medical oncology has undergone a marked evolution in recent decades, moving 
from the chemotherapeutic era in which the drugs were non-specifically directed against highly 
proliferative cells, towards an era of novel targeted therapy in which drugs and their combinations 
target specific mechanisms of tumor cell growth and survival.
1
 Some targeted agents have changed 
the treatment paradigm in solid and hematological tumors, such as anti-erb2 monoclonal antibodies 
(MoAbs) in breast cancer, tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib) in 
chronic myeloid leukemia, anti-CD20 MoAb in non-Hodgkin lymphoma, anti-VEGF-R MoAb in 
colon cancer and anti-BRAF in melanoma. 
Multiple myeloma (MM) has followed a similar pattern in recent years: alkylators such as 
melphalan along with steroids have been the standard agents for the care of these patients for over 
30 years. However, in the last decade, several agents (proteasome inhibitors and IMIDs) with 
singular mechanisms of action have been discovered, developed and approved.
2, 3
 These advances 
have resulted in a clear improvement in the outcome of MM patients,
4
 but despite this, MM remains 
incurable and patients who become refractory or ineligible to receive bortezomib and IMIDs have a 
dismal prognosis.
5
 This situation along with the pattern of subsequent responses/relapses that 
characterize the evolution of MM highlights the need for novel drugs. The investigation and 
discovery of these new drugs and, in particular, their use in combinations, should be based on a 
thorough knowledge and understanding of the pathogenesis of cancer
6
, specifically that of MM.
7–9
 
MM is probably one of the malignant diseases for which more active research into novel 
antitumoral agents has been carried out. However, only a few agents have successfully completed 
the early phases of clinical development. Moreover, the large number of novel agents under 
investigation has created some confusion in the clinical arena, whereby there is no consensus about 
which of them have clinically relevant antitumor activity. The purpose of this manuscript is to 
review and shed light on the rationale for the use and the clinical results obtained to date for the 
most promising novel agents currently under investigation. These agents have been divided into two 
main groups: first, those agents derived from the already approved and active agents (such as 
second- and third-generation proteasome inhibitors, immunomodulatory agents and alkylators) and 
second, (the main focus of this review), drugs with novel mechanisms of action, such as monoclonal 
antibodies, agents acting on the cell cycle, deacetylase inhibitors, agents acting on the unfolded 
protein response, signaling pathway inhibitors, and kinase inhibitors. Figure 1 illustrates a 
schematic representation of the main drugs that have been tested in MM and the mechanisms they 
target. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Schematic representation of the main targets in MM plasma cells and the drugs tested against them 
 
For ease of reading, the mechanism of action is highlighted in italics, and the clinical results are 
detailed in the tables, with only the most relevant aspects discussed in the text. Once the 
mechanistic and clinical data has been presented, the discussion will analyze the future of this field 
of novel agents, emphasizing which of them seem more promising and how they should be 
developed. 
Agents derived from those with proven clinical efficacy in MM 
1. Novel proteasome inhibitors 
One of the major advances in the treatment of MM patients in recent years has been the discovery 
of the catalytic activity of proteasomes,
10
 along with the synthesis of bortezomib (PS-341),
11
 the 
first-in-class proteasome inhibitor, which has demonstrated striking clinical
12–14
 efficacy in MM. 
The anti-MM activity of the inhibition of this pathway is the consequence of several biological 
effects,
15–17
 among which, the following are highlighted: 1) the accumulation of cyclin- or CDK-
inhibitors and tumor suppressor proteins, 2) the inhibition of the clearance of misfolded proteins 
(inducing endoplasmic reticulum, stress and activation of the unfolded protein response),
18,19
 and 3) 
the blockade of the NF-κB transcription factor pathway through the prevention of IκB (Inhibitor of 
NF-κB) degradation after its polyubiquitination by IKK (IκB kinase).20 After bortezomib, several 
other proteasome inhibitors have been synthesized and are at different stages of clinical 
development. Some of them, as is the case of ixazomib (MLN-9708), are also boronate peptides, 
however, other structural families have been developed: the epoxyketones, including carfilzomib 
(PR-171) and oprozomib (ONX-0912 or PR-047), and the salinosporamides such as marizomib 
(NPI-0052). They differ in their biological properties as they target different catalytic subunits of 
the proteasome. Boronic acid containing PIs (bortezomib and ixazomib) inhibit both the 
chymotrypsin-like and the caspase-like activities of the proteasome, while carfilzomib and 
oprozomib are selective of chymotrypsin-like activity. Marizomib, by contrast, has a broader 
pattern of inhibition since it targets the three catalytic activities. The other major difference is the 
reversibility of the inhibition and, in this regard, carfilzomib, oprozomib and marizomib, unlike 
bortezomib and ixazomib, induce irreversible inhibition. Finally, some of these novel agents (such 
as ixazomib or oprozomib) are orally bioavailable. Table 1 summarizes the clinical data of these 
novel proteasome inhibitors used in monotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
Summary of the most relevant clinical trials with novel proteasome inhibitors in monotherapy in 
relapsed/refractory MM 
 
Carfilzomib is FDA-approved for the treatment of MM patients who have received at least two 
previous therapies, including bortezomib and an immunomodulatory agent, and are refractory to 
their last therapy. As a monotherapy, this drug induced an overall response rate (ORR) of 52% in 
bortezomib-naïve patients,
21
 and approximately 20% of patients refractory to bortezomib responded 
to carfilzomib.
22, 23
 Based on this, a phase 3 randomized trial (Focus) has compared carfilzomib 
with best supportive care in MM patients for whom no other therapeutic option is available. 
With respect to safety, the most frequent grade 3 (G3) AEs were hematological with very mild 
peripheral neuropathy.
24
 However, other non-hematologic toxicities, albeit rare, have emerged, 
including cardiopulmonary or renal toxicity. Nevertheless, carfilzomib was also safe in patients 
with renal impairment in a trial specifically designed to evaluate this issue.
25
 
Several drug combinations are currently being explored, including that of carfilzomib with 
lenalidomide and dexamethasone both in relapsed refractory patients,
26
 (basis for the phase 3 Aspire 
trial
27
) and in newly diagnosed patients. 
28, 29
 Also in newly diagnosed, carfilzomib + thalidomide + 
dexamethasone has been tested,
30
 even with the addition of cyclophosphamide.
31
 Moreover, 
carfilzomib plus steroids have also been combined in transplant ineligible newly diagnosed patients, 
with cyclophosphamide
32
 and with melphalan.
33
 Other innovative combinations are being explored 
with novel drugs such as histone deacetylase inhibitors,
34–36
 pomalidomide,
37
 and the kinase spindle 
protein inhibitor Arry-520,
38, 39
 in relapsed and refractory patients. 
The second-generation compound oprozomib (ONX-0912; previously PR-047),
40
 is a structural 
analog of carfilzomib that is orally bioavailable. Oprozomib capsules administered in split doses 
demonstrated clinical activity in a phase 1 trial in patients with hematologic malignancies (MM & 
CLL).
41
 In order to improve gastrointestinal tolerability, a once-daily administered tablet was 
introduced in this phase 1b/2 trial with 16 MM and 5 Waldenström’s macroglobulinemia (WM) 
patients already enrolled with a good safety profile and promising preliminary response data.
42
 
Ixazomib (MLN9708) is the first orally bioavailable proteasome inhibitor evaluated to date in 
clinical studies for the treatment of MM. Two studies are exploring its activity in monotherapy in 
relapsed/refractory MM patients previously exposed to proteasome inhibitors still with very 
preliminary results (table 1).
43,44
 With respect to toxicity, the most remarkable finding was the low 
rates of significant PN, although treatment related rash has been noted. Ixazomib is also being 
examined in combination with melphalan and prednisone
45
 and with lenalidomide and low-dose 
dexamethasone
46
 in newly diagnosed patients. 
Marizomib (NPI-0052) is still in the early stages of development, showing minimal peripheral 
neuropathy with 15–20% ORR in heavily pretreated patients (table 1).47 
2. Novel IMIDs 
Since the discovery of the anti-MM activity of thalidomide,
48, 49
 several thalidomide analogs 
(lenalidomide-CC-5013 or pomalidomide-CC-4047) have been developed. Drugs in this group are 
called immunomodulatory drugs (IMIDs) due to their action on the immune system. Recent studies 
suggest that IMIDs exert their function by binding to cereblon, a molecule that forms an E3 
ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A.
50
 In fact, the 
absence of cereblon is associated with resistance to IMIDs,
51,52
 and the teratogenic potential of this 
family of drugs has also been linked to the binding to this protein.
50
 Although their precise mode of 
action is not well established, three mechanisms have been implicated in their antimyeloma activity: 
tumoricidal, immunomodulatory and antiangiogenic. The tumoricidal activity of lenalidomide may 
be mediated by several mechanisms: 1) down regulation of IRF4 levels
53, 54
 that lead to an initial G1 
cell cycle arrest, decreased cell proliferation, and cell death associated with a decrease in MYC 
levels and the induction of several CDK inhibitors (p15, p16, p21 and p27);
55, 56
 2) induction of p21 
WAF-1 expression through an LSD1-mediated epigenetic mechanism;
57
 and 3) disruption of the 
interaction between tumor cells and their microenvironment.
55, 58
 The immunomodulatory effect is 
mediated through the augmentation of natural killer (NK) cytotoxicity,
59, 60
 the inhibition of 
regulatory T cells,
61
 or the restoration of the immune synapse formation.
62
 Thalidomide
48, 49
 and 
lenalidomide
63–65
 were approved in the last decade for the treatment of MM patients. However, 
pomalidomide has recently emerged as a very potent IMID, both alone and in several combinations 
(table 2). In this regard, similarly to lenalidomide and thalidomide, the addition of dexamethasone 
induces synergy, improving the response rate and the PFS,
66
 and this combination in the initial 
phase 2 study by Lacy and co-workers induced a 62% response rate with a PFS of 13 months (table 
2),
67
 similar to that previously obtained with lenalidomide + dexamethasone.
63–65
 This is relevant 
considering that, in this trial, 62% of the patients had been previously exposed to IMIDs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
Summary of the most relevant clinical trials with pomalidomide in relapsed MM patients 
 
  
Several trials have explored the activity of pomalidomide + dexamethasone in lenalidomide-
refractory patients
68, 69
 or in lenalidomide and bortezomib refractory patients.
69–71
 In these trials, 
approximately one-third of patients achieved at least PR and the PFS ranged from 3.3 to 7.7 months 
(table 2). 
Regarding the optimal dose and schedule of administration (2 vs. 4 mg or 21/28 vs. 28/28 days), 
several schedules have been used and compared (see table 2).
69–71
 Based on these, although other 
possibilities may be acceptable, the dose of 4 mg on days 1–21 followed by a one-week rest period 
has been chosen as the standard for the subsequent randomized trials. 
All these studies were the bases for the phase 3 trial (MM-003) in which MM patients that had 
failed both lenalidomide and bortezomib and were refractory to their last therapy, were randomized 
to receive pomalidomide + low dose dexamethasone vs high dose dexamethasone. There was a 
significant advantage for the pomalidomide arm over dexamethasone in terms of ORR (31% vs 
10%), PFS (4 vs 1.9 months) and OS (NR vs 7.8 months).
72
 Also pomalidomide has been tested in 
genomically defined high risk relapsed MM patients with some activity in this setting.
73
 
The safety profile of this agent is quite similar to that of lenalidomide, with hematological side 
effects being the main source of toxicity, with low rates of deep venous thrombosis, especially 
when using prophylactic measures. 
As with carfilzomib, several trials in relapsed/refractory patients are already testing the activity of 
pomalidomide and dexamethasone in combination with several agents (Table 2). 
3. Novel alkylators 
Bendamustine has a quite unusual mechanism of action, since it combines an alkylator structure 
with a purine analog ring. In combination with prednisone it has already been approved in Europe 
for the treatment of newly diagnosed MM patients who are not candidates for ASCT and who are 
not eligible to receive proteasome inhibitors or thalidomide due to preexisting neuropathy. This was 
based on a phase III trial that compared bendamustine + prednisone with melphalan + prednisone in 
newly diagnosed patients, and showed a benefit especially in terms of TTP (14 vs. 10 months).
74
 
Several pilot phase II studies have evaluated the activity of this agent in different combinations in 
relapsed refractory MM: with bortezomib (50%–75% ORR in combination with dexamethasone),75–
79
 thalidomide (26%–86% ORR),80–82 or, more recently, lenalidomide (52%–76% ORR with 24%–
33% VGPR).
83, 84
 Results are quite variable, reflecting the heterogeneity of the patient population 
included in the different trials (mainly with regard to previous lines of therapy). Another novel 
alkylator undergoing with promising pre clinical testing is melphalan-flufenamide (mel-flufen), a 
novel dipeptide prodrug of melphalan. It consists of melphalan conjugated to an amino acid, 
phenylalanine, creating a dipeptide with higher antimyeloma potency than the parental drug based 
on a preferential delivery of melphalan to tumor cells due to the intracellular cleavage of melflufen 
by some peptidases overexpressed in malignant cells.
85
 Another alkylator with the peculiarity of 
being activated when in an hypoxic niche, TH-302, has been developed and tested but due to their 
particular mechanism, the clinical data is included in the last chapter of this review. 
Agents with novel mechanisms of action 
1. Immunotherapy/Monoclonal Antibodies 
Activating the immune system against MM is one of the areas in which a more extensive 
investigation is being made. One of the agents included in this family are monoclonal antibodies 
(MoAbs) that are one of the paradigms of targeted therapy since they are specifically directed 
against antigens present in tumor cells. Once bound, they induce their antitumoral effect through 
several mechanisms:
86, 87
 1) direct cytotoxicity, which can be due to the direct induction of 
apoptosis or to the conjugation with radioisotopes or toxins; 2) to the enhancement of the immune 
function through antigen-dependent cellular cytotoxicity (ADCC) or complement-dependent 
cytotoxicity (CDC). Rituximab (anti-CD20) was the first of these agents to be tested in MM, with 
discouraging results, as it was used as a debulking drug. whereas it might be more effective against 
immature CD20+ cells. Since then, several other MoAbs have been tested in MM (table 3).
78,79
 
 
Table 3 
Summary of the most relevant clinical trials with monoclonal antibodies, alone and in combination with 
other agents in relapsed MM 
 
 
Elotuzumab is the best evaluated of these agents in MM. It is directed against CS1, a glycoprotein 
that is highly specific to plasma cells, although it may also be expressed in NK and CD8+ T cells. 
Although the results in monotherapy were modest (with stable disease as best response),
88
 the 
combination with lenalidomide and dexamethasone has given excellent results with more than 80% 
PR in relapsed patients and what is more important, prolonged PFS (33 months in the last 
update).
89–91
 The proposed mechanism of action of the synergy is an immune-mediated mechanism: 
lenalidomide would prepare the NK and lymphoid cells by, among other mechanisms, changing the 
conformation of their cytoskeleton, to favor the immune recognition, and elotuzumab would modify 
the plasma cells to be more prone to be targeted by the immune cells. A phase III registration 
enabling trial in relapsed myeloma comparing lenalidomide + dexamethasone with lenalidomide + 
dexamethasone + elotuzumab has just been completed. 
CD38, CD138, CD56, and CD40 are other antigens of the plasma cells that have been targeted by 
MoAbs. Daratumumab is an anti-CD38 antibody designed to induce the killing of myeloma cells by 
the three proposed mechanisms. In the dose-escalation study with daratumumab monotherapy, in a 
very heavily pretreated population, 42% of them achieved at least PR at doses considered to reach 
therapeutic levels (≥ 4 mg/kg) (table 3).92, 93 These results are highly promising for a drug used in 
monotherapy in patients with a median of six previous treatments. This has prompted the 
development of other antiCD38 MoAbs, such as SAR650984, which has a similar profile and is 
already being tested in phase I clinical trials. Lorvotuzumab and nBT062 are two antibodies 
directed against CD56 and CD138, respectively. They have in common that they are conjugated 
with a cytotoxic agent (DM1 and DM4, respectively) that is released inside the plasma cell once 
bound to it. The results of the phase 1 trials in monotherapy showed some MRs and even PRs in 
very heavily pretreated patients (table 3).
94–96
 Two MoAbs against CD40, dacetuzumab and 
lucatumumab, have been designed, both of which have shown modest responses as monotherapy 
(table 3).
97, 98
 Some of these antibodies are currently being combined with other agents, several of 
them with lenalidomide and dexamethasone (table 3), in the search for a potential immune synergy. 
BAFF (B-cell activating factor) is a member of the tumor necrosis factor superfamily that promotes 
the survival of malignant B cells, including those in MM. An anti-BAFF MoAb, tabalumab, has 
been combined with bortezomib with or without dexamethasone with 46% achieving PR or better 
(table 3).
99
 Siltuximab has a different mechanism as it is not directed against surface antigens but it 
targets soluble IL-6. Its purpose is to sequester this cytokine and prevent its binding to IL6-R. Two 
phase 2 trials in combination with dexamethasone or with bortezomib and dexamethasone have 
been carried out, yielding ORRs of 19% and 57%, respectively (table 3).
100, 101
 However, the results 
of the randomized trial that compared melfalan + Prednisone + bortezomib with or without 
siltuximab in newly diagnosed MM patients, were not positive, as there were no significant 
differences in terms of responses, PFS or OS.
102
 
IPH2101 is an anti-KIR antibody that aims to block the immunotolerance induced by HLA class I 
molecules of MM cells when they bind to NK cell inhibitory killer immunoglobulin-like receptors 
(KIRs). No responses have been observed in monotherapy
103
 and only modest activity (31% ≥ PR) 
has been noted in combination with lenalidomide (table 6).
104
 
 
Table 6 
Summary of the most relevant clinical trials with Hsp-90 inhibitors, agents interfering with signaling 
pathways, and agents with other mechanisms of action in MM 
 
2. DAC inhibitors 
Deacetylases (DACs) are enzymes specialized in the removal of acetyl groups from several 
proteins. They have a role in oncogenesis through their epigenetic activity of targeting histones, but 
also through their regulation of non-histone proteins relevant to tumor progression, such as p53, 
E2F family members, Bcl-6, Hsp90, HIF-1α, and Nur77.105, 106 DACs are also overexpressed in 
several tumors, including MM, which has prompted the development of DAC inhibitors (DACis) 
for antitumoral purposes. There is a particular rationale for using these agents in MM in the search 
for some specific DACi mechanisms; the inhibition of the epigenetic inactivation of p53 and the 
blockade of the unfolded protein response, through the inhibition of the aggresome formation and 
autophagy (by targeting DAC6) and the inactivation of the chaperone system (by acetylating HSP-
90). 
Four classes of DACs have been described. Class I, II and IV DACs are known as classical DACs 
and are the ones that have been implicated in oncogenesis and are targets of DACis.
105, 107
. Class III 
DACs are called sirtuins, due to their homology with yeast Sir2, and display characteristic features. 
Several DACis have been tested in MM. Despite their promising preclinical activity,
108–113
 their 
clinical efficacy in monotherapy in relapsed/refractory MM patients was very modest (table 5).
114–
117
 This prompted the development of several combinations, among which, the one with the 
strongest scientific rationale is probably that of DACis and proteasome inhibitors. The basis is the 
simultaneous targeting of several mechanisms involved in the unfolded protein response: the 
inhibition of the proteasome blocks the degradation of the ubiquitinated misfolded proteins, and the 
use of DACis interferes with the activity of heat-shock proteins, which are necessary for the correct 
folding of proteins, and with aggresome formation and autophagy (through inhibition of DAC6), 
which is also important for the elimination of toxic misfolded proteins. Overall, this induces the 
accumulation of toxic misfolded proteins in the myelomatous cells with ineffective unfolded protein 
response, leading to apoptosis. The phase 1 trials with several of these DACis in combination with 
bortezomib have produced promising results (table 4),
118–122
 but the phase 3 randomized trial 
(Vantage 088) that compared bortezomib with bortezomib + vorinostat did not confirm them,
123
 
since, although it showed an improved response rate (ORR 56% vs. 41%, P < 0.0001), this 
translated into only a minimal advantage in PFS (7.6 vs. 6.8 months. HR = 0.774 (0.64 – 0.94). p = 
0.010) and no differences in OS (table 4). Another phase 3 randomized trial (Panorama 1) with the 
same rationale but with panobinostat instead of vorinostat and with the addition of dexamethasone 
in both arms has been recently completed, although results are not available yet. A question that 
remains unanswered is whether the addition of a DACi could revert bortezomib resistance. To 
address this, two trials, one with vorinostat and the other with panobinostat, are analyzing the 
activity of their combination with bortezomib (+/− dexamethasone) in bortezomib-refractory 
patients.
124, 125
 Results indicate that around 20–30% of these patients could be rescued by the 
addition of DACi to bortezomib (table 4). 
 
Table 4 
Summary of the most relevant clinical trials with deacetylase inhibitors in MM 
  
Table 5 
Summary of the most relevant clinical trials with inhibitors of proteins acting in cell cycle and other 
kinase inhibitors in MM 
 All these DACis have a broad spectrum of inhibition of DACs, as they are either pan-DACi 
(inhibition of the classes of DAC) or class 1 inhibitors, and this has been associated with significant 
toxicity, which is mainly manifested as general or gastrointestinal symptoms. With the purpose of 
overcoming this, while maintaining efficacy, a novel HDAC-6-specific inhibitor (rocilinostat) has 
been developed. Although no responses were obtained as monotherapy, it showed good 
tolerability
126
 and is currently being combined with bortezomib and lenalidomide, with good 
preliminary results mainly in the combination with the IMID, with 5 out of 6 evaluable patients 
achieving PR or better.
127
 
3. Agents acting on proteins and enzymes involved in the cell cycle 
The only common oncogenic event found in MM patients to date is cyclin D deregulation.
128
 
Therefore, efforts have been made to develop agents that can target the cell cycle abnormalities 
present in MM cells (table 5). The main focus has been the CDKs (cyclin-dependent kinases), 
which are the proteins that phosphorylate and activate these cyclins, in particular CDK 4/6, which is 
responsible for cyclin-D phosphorylation. Seleciclib (PD0332991) is a CDK 4/6 inhibitor that was 
combined with bortezomib using an attractive sequential approach that attempts to synchronize cells 
with the CDK inhibitor and make them more susceptible to the cytotoxic effect of the proteasome 
inhibitor. Nevertheless, results were discouraging and the development of this compound in MM 
was stopped. Other compounds evaluated in cell cycle have been those involved in the spindle 
formation and function: aurora kinase A inhibitors, such as the novel MLN8237, whose 
combination with bortezomib has been recently reported, with 52% of patients achieving at least 
MR and 26% PR or better (table 5).
129
 
KSP (kinesin spindle protein) is a member of the kinesin superfamily of microtubule-based motors; 
it plays a critical role in mitosis as it mediates centrosome separation and bipolar spindle assembly 
and maintenance. Arry-520 is a KSP inhibitor that by blocking this protein, arrests cells in mitosis 
and subsequently induces apoptosis through the degradation of survival signals. The drug on its 
own has already shown up to 16% PR or better
130, 131
 and 22% in combination with 
dexamethasone
131
 in very refractory patients with a median of six and ten previous lines of therapy 
respectively (table 5). It is already being combined with proteasome inhibitors such as bortezomib 
and carfilzomib and is one of the most promising agents currently under exploration. 
4. Kinase inhibitors 
Several tyrosine or serine-threonine kinase inhibitors have been grouped within this section of the 
review. They have been clinically investigated in MM, yielding different outcomes (table 5). One of 
the most recent is the CDK inhibitor dinaciclib. It inhibits CDK 1, 2, 5 and 9 and is included in this 
rather than the previous section because it was selected on the basis of its CDK-5 inhibitory 
activity, which is not related to the cell cycle. CDK-5 inhibition was identified as one of the top 
bortezomib-sensitizing mechanisms in high-throughput RNAi screening.
132
 This inhibitor shows 
some activity as a single agent (18 ≥ MR and 11% ≥ PR; table 5),133 and may synergize with 
bortezomib. Among the tyrosine kinase inhibitors, those with the best rationale for use in MM are 
probably the FGFR3 inhibitors in patients with t(4;14). Two small molecules
134, 135
 and one 
MoAb
136
 have been explored in patients with this translocation, with disappointing results (table 5). 
Inhibitors of cKit/PDGFR have also been tested: imatinib did not induce any response
137
 and 
dasatinib, demonstrating 5% response in monotherapy,
138
 has been tested with bortezomib and 
lenalidomide (table 5).
139
 This gave some responses but it was difficult to assess whether dasatinib 
added anything to the combination of agents. Other inhibitors are the anti-VEGF-R MoAb 
bevacizumab, which, in combination with lenalidomide, induced 71% of PR or better,
140
 and IGF1-
R,
141, 142
 EGF-R
143
 and PKC
144
 inhibitors that did not respond in monotherapy, but may have some 
role in combination with other agents such as bortezomib (table 5). 
5. Agents acting on the unfolded protein response (UPR) pathway 
The chaperone system is responsible for the correct folding of proteins. Its malfunctioning therefore 
induces the accumulation of misfolded proteins and activates the unfolded protein response. Heat-
shock 90 proteins (Hsp-90) are amongst the main members of this system, and represent a potential 
target for use in myeloma treatment. Similarly to DACis, there is a good rationale for combining 
Hsp-90 inhibitors with proteasome inhibitors in order to achieve synergistic activation of the 
unfolded protein response. In fact, one of these Hsp-90 inhibitors, tanespimycin, has been combined 
with bortezomib and dexamethasone in two phase 1 trials, giving an ORR of up to 15% in patients 
who had received five previous lines of therapy (table 6).
145, 146
 AUY922, another drug of this 
family, has also been combined with bortezomib +/− dexamethasone in relapsed/refractory patients, 
without reported clinical results yet. 
Other agents that could have a role in this important pathway are the purine scaffold HSP90 
inhibitors or the IRE1alpha inhibitors, but they are still in preclinical phases of development. 
6. Signal transduction pathway inhibitors 
Myeloma cells, like other tumor cells, are characterized by an abnormal activation of several of the 
most important signaling pathways, such as the PI3K/AKT/mTOR, RAF/MEK/ERK, JAK/STAT 
and NFkB pathways. This has prompted the development of several drugs aimed at blocking these 
routes at different levels. One of the main types is the group of proteasome inhibitors, which 
interfere with the NFkB pathway by hampering the degradation of the inhibition of NFkB (IkB) by 
the proteasome. Other more selective inhibitors of different components of these pathways are 
summarized in table 6. 
The PI3K/AKT/mTOR pathway has been extensively studied and targeted, as it is probably one of 
the most important in MM pathogenesis. AKT inhibitors such as perifosine
147
 have been combined 
with bortezomib (in the search for the synergistic inhibition of AKT with perifosine and ERK with 
bortezomib)
148
 or with lenalidomide,
149
 with up to 32% and 50% with at least PR, respectively 
(table 6). GSK211083 is another novel AKT inhibitor that is active in monotherapy (9% ≥ PR. 
Table 6).
150
 The mTOR complexes lie downstream of this pathway. Two compounds targeting 
mTORC1, everolimus and temsirolimus, have been tested, with 6% and 7% PR in monotherapy, 
respectively.
151, 152
 These values improved when the compounds were combined with bortezomib
153
 
or lenalidomide
154–156
 in more heavily pretreated patients (table 6). Recently, MLN1018, a new 
mTOR inhibitor targeting the mTOR-C1 and mTOR-C2 complexes, has been tested but no 
responses were observed in monotherapy (table 6).
157
 
The RAS/RAF/MEK/ERK pathway was the second to be investigated, addressing not only the 
blockade of top upstream molecules of the pathway by the farnesyl-transferase inhibitor 
tipifarnib,
158
 which impedes the activation of RAS, to MEK inhibitors such as selumetinib (ARRY-
6244),
159
 but also the p38/MAPK inhibitor SCIO-469, which has been combined with 
bortezomib.
160
 Another interesting drug, is the p38/JNK activator Plitidepsin, which after showing 
activity in heavily pretreated patients in the phase II trial (table 6), is currently in phase 3 
evaluation.
161
 Of these, selumetinib is probably the most promising, since, as a single agent, it has 
given an 8% PR in patients with five previous lines of therapy (table 6). Recently, whole genome 
sequencing revealed activating mutations of the kinase BRAF in 4% MM patients.
162
 Vemurafenib, 
a small molecule inhibitor specifically targeting V600E-mutated BRAF, has been reported to induce 
a PR in a patient relapsing after several lines of therapy and harboring this mutation.
163
 
7. Drugs with different mechanisms of action 
The search for ligands of death receptors (FAS or TRAIL-R) that directly activate the extrinsic 
pathway of apoptosis has always been an area of interest in the field of novel antitumoral agents, 
although, to date, they have not shown significant efficacy and have been quite toxic. However, 
recent promising preliminary results from two trials in monotherapy with a circularly permuted 
TRAIL (CPT) have registered 19% and 33% PR or better.
164, 165
 This agent has also been combined 
with thalidomide, with 22% with at least PR and 34% with at least MR in thalidomide-refractory 
patients (table 6).
166
 
Two novel agents share a common mechanism of DNA damage induction or DNA repair inhibition. 
Zalypsis is a marine-derived compound that binds to the minor groove of DNA and induces DNA 
double-strand breaks. As a single agent in patients with a median of three previous lines of therapy 
it has given 31% MR or better, including 6% PR. (table 6).
167
 The other agent is the PARP 1/2 
inhibitor, velaparib, which has been combined with bortezomib in the search for a synergistic 
combination of DNA damage induction and DNA repair inhibition, and has resulted in 50% PR 
(table 6).
168
 
The presence of a hypoxic niche in the bone marrow has been associated with MM pathogenesis.
169
 
In this regard, TH-302, an alkylator designed to be activated by hypoxia has been developed and 
clinically tested in combination with dexamethasone, with some responses (22% PR and 22% MR) 
in heavily pretreated patients.
170
 
Discussion 
The incurable nature of MM makes it necessary to increase the treatment armamentarium against 
this disease. As it is shown in this review, the ongoing extensive research and the already positive 
clinical results with several agents, makes the future optimistic in the aim of transforming MM into 
a chronic disease. Although none of the agents with novel mechanisms of action (after proteasome 
inhibitors or IMIDs) are still approved, it is reasonable to think that several of them will be in the 
near future. The initial approval for most of them will be for patients refractory to proteasome 
inhibitors and IMIDs, but its use will be soon expanded to other settings and used in different 
combinations. Particularly valuable may be for newly diagnosed patients, where the disease is more 
sensitive, and probably the use of optimized multitargeted combinations in these patients could 
derive in the curability of some of them. 
Nevertheless, this optimism should be balanced with the reality of the clinical results, since, many 
of the novel agents, despite having a good scientific rationale and promising activity in preclinical 
models of MM, have not demonstrated clinical activity. This discordance may be due to several 
reasons, one of them being the limitations of the preclinical models of MM to accurately reflect the 
patient’s setting. The other obvious issue is the heterogenetic and multigenetic nature of MM, and 
the pathogenesis of a complex malignancy, which seems to rely not only on one unique hit but on 
many of them. An example of this is that, although cyclin-D is deregulated in the vast majority of 
MM patients, agents targeting this mechanism have not produced the expected clinical results. 
In fact, agents with a quite pleiotropic mechanism of action such as proteasome inhibitors, 
immunomodulatory agents or alkylators are those that have demonstrated to be effective in MM and 
therefore, along with steroids, have become the backbone of the treatment of MM patients. 
Nevertheless, not all agents with a broad spectrum of mechanisms have been effective in MM. As 
previously shown, DACi, which target several different proteins and mechanisms in the tumor cell, 
have not confirmed the expectations in the dual combination, based on the results of the phase 3 
Vantage trial recently reported. However, data on a triple combination with corticosteroids is still 
pending (Panorama 1 trial); moreover, it could be that the use of more specific DACi such as the 
HDAC6 specific, rocilinostat may result in higher efficacy due to a more favorable toxicity profile 
that would translate into a prolonged drug exposure. 
The results of the so-called targeted agents, that display quite specific mechanisms of action, when 
used in monotherapy, are usually not very optimistic, but we also have to consider that most of 
these trials have been performed in quite heavily pretreated patients. Accordingly, the lack of 
activity as single agents, should probably not preclude the future investigation of these drugs in 
MM in scientifically based combinations. A good example of this situation is the combination of 
the anti-CS1 MoAb elotuzumab with lenalidomide and dexamethasone; despite the lack of efficacy 
of elotuzumab as single agent, it has yielded remarkable results in terms of response rate, but 
particularly in terms of PFS (33 months) in the relapsed/refractory setting, based on the potentiation 
of an anti-MM immune response. This leads to an important point, as most of these novel agents in 
monotherapy does not induce long PFS, probably reflecting again the bad prognosis of the patients 
included in these trials, but also the fact that cells are able to rather quickly overcome the effects of 
these targeted drugs and develop mechanisms of resistance. Probably, the use of rationally based 
combinations as the one just mentioned, could avoid the development of this resistance and increase 
the durability of the responses. 
One of the most promising strategies in the current arena is immunotherapy. This approach has been 
traditionally used in several cancers, and specifically in MM. In this regard we cannot forget the use 
of interferon, whose use was stopped due to the low tolerability but that showed benefit in the 
maintenance setting. Several decades later, a novel family of agents, IMIDs, appeared in the 
treatment armamentarium of MM, cooperating in the revolution of MM therapy and outcome. In 
this same line, immunotherapy with BCMA chimeric antigen receptors,
171
 dendritic cell/myeloma 
fusion cellular vaccine
172
 or the incorporation of the PD-1/PDL-1 axis antagonists 
173, 174
 may 
harness the body’s own immune system, generating an anti-tumor response have been preclinically 
explored. Quite recently, several drugs and combinations that are based on immunological 
mechanisms have appeared and are currently being tested in the clinics. This is the case of different 
MoAb that target surface molecules of the malignant plasma cell. In addition to the already 
mentioned elotuzumab, there are several other MoAb that by inducing direct cytotoxicity and, 
mainly, ADCC and CDC have raised quite interest. Probably the most exciting target is CD38, 
against which several antibodies have been developed. The most advanced of these antibodies, 
daratumumab, has demonstrated clear activity as monotherapy in heavily pretreated patients with 
42% responses at therapeutic doses. 
Several other of the currently tested agents have also already shown some activity in monotherapy. 
One of the most promising is the KSP inhibitor Arry-520, which alone or in combination with 
dexamethasone in very refractory patients, has produced 10–16% responses. This agent is now 
being investigated in several combinations with novel and conventional agents. The CDK5 
inhibitor, identified in an RNAi screening of druggable targets, induced responses in 11% of cases, 
but, probably, the combination with bortezomib is expected to be more potent, based on the 
preclinical rationale. Other agents with some responses as single agents, although in more 
preliminary stages of development are agents targeting different signaling pathways such as 
PI3K/AKT/mTOR inhibitors and the novel MEK inhibitor selumetinib, all of which produce 5–10% 
PR. Also among these signaling pathways-specific agents we can emphasize aplidin, a p38, JNK 
activator with efficacy in the phase 2 trial, and that is being evaluated in a phase 3 trial in 
combination with dexamethasone. 
Before the availability of the recently approved drugs, the limited availability of agents did not 
allow the selection of a particular therapy for a particular patient, and treatment was standard for all 
patients, with the only differentiation being based on age and transplant elegibility. The 
development of the novel agents has prompted the initiation of more personalized of therapy, in 
order to investigate the activity of new drugs/combinations in selected cohorts of patients, based on 
cytogenetic, molecular, or clinical (extramedullary disease). Moreover, biomarkers for 
sensitivity/resistance to particular drugs are under way. Examples of this situation is the use of 
CRBN to stratify patients sensitive or resistant to IMIDs or the measurement of serum AAG to also 
detect patients that will not respond to Arry-520. 
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